Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXP604 for Mild to Moderate COVID-19
NCT05381519Phase 2Unknown
- Sponsor
- Wuhan Institute of Biological Products
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing DXP604 with Placebo (2 arms). Primary endpoint: viral load of SARS-CoV-2 virus in nasopharyngeal swab samples at Day 8. Status: unknown.
02
Drugs
DXP-604
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05381519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381519.